image
Healthcare - Medical - Devices - NASDAQ - US
$ 13.91
-1.56 %
$ 338 M
Market Cap
-5.17
P/E
1. INTRINSIC VALUE

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.[ Read More ]

The intrinsic value of one CVRX stock under the base case scenario is HIDDEN Compared to the current market price of 13.9 USD, CVRx, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CVRX

image
FINANCIALS
39.3 M REVENUE
74.89%
-43.1 M OPERATING INCOME
-1.35%
-41.2 M NET INCOME
0.55%
-39 M OPERATING CASH FLOW
8.57%
-591 K INVESTING CASH FLOW
13.72%
24 M FINANCING CASH FLOW
220.09%
13.4 M REVENUE
13.26%
-13 M OPERATING INCOME
6.88%
-13.1 M NET INCOME
6.63%
-10.4 M OPERATING CASH FLOW
-5.90%
-37 K INVESTING CASH FLOW
89.58%
40.2 M FINANCING CASH FLOW
8417.37%
Balance Sheet Decomposition CVRx, Inc.
image
Current Assets 112 M
Cash & Short-Term Investments 90.6 M
Receivables 7.55 M
Other Current Assets 14 M
Non-Current Assets 3.14 M
Long-Term Investments 0
PP&E 3.11 M
Other Non-Current Assets 27 K
Current Liabilities 7.86 M
Accounts Payable 1.88 M
Short-Term Debt 231 K
Other Current Liabilities 5.75 M
Non-Current Liabilities 31.4 M
Long-Term Debt 31.5 M
Other Non-Current Liabilities -124 K
EFFICIENCY
Earnings Waterfall CVRx, Inc.
image
Revenue 39.3 M
Cost Of Revenue 6.26 M
Gross Profit 33 M
Operating Expenses 76.1 M
Operating Income -43.1 M
Other Expenses -1.9 M
Net Income -41.2 M
RATIOS
84.08% GROSS MARGIN
84.08%
-109.69% OPERATING MARGIN
-109.69%
-104.85% NET MARGIN
-104.85%
-54.25% ROE
-54.25%
-35.75% ROA
-35.75%
-40.68% ROIC
-40.68%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CVRx, Inc.
image
Net Income -41.2 M
Depreciation & Amortization 522 K
Capital Expenditures -591 K
Stock-Based Compensation 6.3 M
Change in Working Capital -4.8 M
Others 1.26 M
Free Cash Flow -39.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CVRx, Inc.
image
Wall Street analysts predict an average 1-year price target for CVRX of $15.9 , with forecasts ranging from a low of $12 to a high of $23 .
CVRX Lowest Price Target Wall Street Target
12 USD -13.73%
CVRX Average Price Target Wall Street Target
15.9 USD 14.00%
CVRX Highest Price Target Wall Street Target
23 USD 65.35%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership CVRx, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
152 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
323 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 15, 2024
Bought 24.3 K USD
SLATTERY JOSEPH P
Director
+ 3000
8.1 USD
3 months ago
Aug 08, 2024
Bought 24.7 K USD
SLATTERY JOSEPH P
Director
+ 3000
8.2386 USD
3 months ago
Aug 06, 2024
Bought 22.7 K USD
SLATTERY JOSEPH P
Director
+ 2500
9.09 USD
3 months ago
Aug 05, 2024
Bought 251 K USD
Hykes Kevin
PRES & CEO
+ 30000
8.3589 USD
9 months ago
Feb 16, 2024
Sell 96.1 K USD
JOHNSON & JOHNSON
10 percent owner
- 3725
25.81 USD
8 months ago
Feb 20, 2024
Sell 55.7 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 2545
21.905 USD
1 year ago
Aug 03, 2023
Sell 11.7 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 628
18.5549 USD
1 year ago
Jul 31, 2023
Sell 19.6 K USD
VERRASTRO PAUL
CHIEF MKTG & STRAT OFFICER
- 1122
17.4948 USD
1 year ago
Nov 28, 2022
Sell 47.4 K USD
VERRASTRO PAUL
director: CHIEF MKTG & STRAT OFFICER
- 4000
11.8545 USD
1 year ago
Nov 28, 2022
Sell 7.51 K USD
VERRASTRO PAUL
director: CHIEF MKTG & STRAT OFFICER
- 600
12.5217 USD
2 years ago
May 24, 2022
Bought 40.8 K USD
Nielsen Kirk G.
director:
+ 8070
5.0498 USD
2 years ago
May 23, 2022
Bought 22.3 K USD
Nielsen Kirk G.
Director
+ 4432
5.0396 USD
2 years ago
May 20, 2022
Bought 67.4 K USD
Nielsen Kirk G.
Director
+ 13387
5.0354 USD
2 years ago
May 19, 2022
Bought 55.3 K USD
Nielsen Kirk G.
director:
+ 10976
5.038 USD
2 years ago
May 03, 2022
Bought 23.9 K USD
Nielsen Kirk G.
director:
+ 3992
5.996 USD
2 years ago
May 04, 2022
Bought 153 K USD
Nielsen Kirk G.
Director
+ 25503
5.9899 USD
2 years ago
May 03, 2022
Bought 197 K USD
Nielsen Kirk G.
Director
+ 32809
5.9972 USD
2 years ago
Apr 28, 2022
Bought 251 K USD
Nielsen Kirk G.
director:
+ 41988
5.9701 USD
2 years ago
Apr 28, 2022
Bought 597 USD
Nielsen Kirk G.
Director
+ 100
5.97 USD
2 years ago
Feb 28, 2022
Bought 5.42 K USD
Jain Mudit K.
Director
+ 600
9.0327 USD
2 years ago
Feb 24, 2022
Bought 28 K USD
Nielsen Kirk G.
Director
+ 3400
8.2381 USD
2 years ago
Feb 23, 2022
Bought 307 K USD
Nielsen Kirk G.
Director
+ 38200
8.0404 USD
2 years ago
Feb 22, 2022
Bought 318 K USD
Nielsen Kirk G.
Director
+ 40008
7.9399 USD
2 years ago
Feb 18, 2022
Bought 211 K USD
Nielsen Kirk G.
Director
+ 26659
7.9233 USD
2 years ago
Nov 19, 2021
Bought 4.11 K USD
Jain Mudit K.
Director
+ 300
13.6875 USD
3 years ago
Nov 18, 2021
Bought 12.8 K USD
Jain Mudit K.
Director
+ 875
14.6327 USD
3 years ago
Aug 12, 2021
Bought 12.3 K USD
Jain Mudit K.
Director
+ 625
19.7248 USD
3 years ago
Jul 02, 2021
Bought 4.06 M USD
NEA PARTNERS 10 L P
10 percent owner
+ 225500
18 USD
3 years ago
Jul 02, 2021
Bought 446 K USD
NEA PARTNERS 10 L P
10 percent owner
+ 24750
18 USD
3 years ago
Jul 02, 2021
Bought 4.06 M USD
NEW ENTERPRISE ASSOCIATES 10 L P
10 percent owner
+ 225500
18 USD
3 years ago
Jul 02, 2021
Bought 4.95 M USD
GLAXOSMITHKLINE PLC
10 percent owner
+ 275000
18 USD
3 years ago
Jul 02, 2021
Bought 500 K USD
NEHRA JOHN M
Director
+ 27777
18 USD
3 years ago
Jul 01, 2021
Bought 1.29 K USD
NEHRA JOHN M
Director
+ 50
25.8 USD
3 years ago
Jun 30, 2021
Bought 1.37 K USD
NEHRA JOHN M
Director
+ 50
27.4257 USD
3 years ago
Jul 02, 2021
Bought 4 M USD
Jain Mudit K.
Director
+ 222222
18 USD
3 years ago
Jul 01, 2021
Bought 25.1 K USD
Jain Mudit K.
Director
+ 1000
25.1 USD
3 years ago
Jul 02, 2021
Bought 4.95 M USD
Pardo Geoffrey B
Director
+ 275000
18 USD
7. News
CVRx: Impressive Top-Line Growth Seems Priced In CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. seekingalpha.com - 1 week ago
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call. seekingalpha.com - 2 weeks ago
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago. zacks.com - 2 weeks ago
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 3 weeks ago
CVRx announces new CPT® Category I codes for Barostim MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure. globenewswire.com - 4 weeks ago
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. globenewswire.com - 1 month ago
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data CVRx announces the publication of positive study data for its Barostim therapy. zacks.com - 2 months ago
CVRx Announces Appointment of Two New Board Members Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members globenewswire.com - 2 months ago
CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Clients to Contact the Firm! NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. accesswire.com - 2 months ago
CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm Today! NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. accesswire.com - 2 months ago
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX. globenewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 months ago
8. Profile Summary

CVRx, Inc. CVRX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 338 M
Dividend Yield 0.00%
Description CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Contact 9201 West Broadway Avenue, Minneapolis, MN, 55445 https://www.cvrx.com
IPO Date June 30, 2021
Employees 200
Officers Mr. Paul Verrastro Chief Marketing & Strategy Officer Mr. Paul Pignato Vice President of Operations Ms. Jonelle R. Burnham Vice President & General Counsel Mr. Jared Oasheim Chief Financial Officer Ms. Tonya A. Austin SPHR Chief Human Resources Officer Dr. Philip B. Adamson M.D., M.Sc. Chief Medical Officer Ms. Bonnie Handke M.B.A., R.N. Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics Mr. Robert Allen John Chief Revenue Officer Ms. Jennifer E. Englund Senior Vice President of Global Clinical Affairs Mr. Kevin Hykes President, Chief Executive Officer & Director